Gustave Roussy and Quinten Health signed a research partnership for the identification of predictive markers of response to immunotherapy in lung cancer

2021, 17 March

| < 1 min read|
Grégoire Dugast

Paris, March 17, 2021 – After decades of innovation and research in immunotherapy, researchers recently turned to a promising new therapeutic strategy that breaks the tolerance acquired by the immune system towards cancer cells. Although this strategy has profoundly changed the fight against certain cancers such as metastatic melanoma, by extending patient life and lowering the risk of relapse, clinicians need appropriate tools to identify patients who are likely to respond to these innovative therapies.

The objective of this partnership is to identify new markers to target populations responding to immunotherapy and to orient non-responders to other more suitable strategies.

By combining the clinical and biological databases and expertise of Gustave Roussy in oncology with the know-how of Quinten Health, a pioneering company in the field of artificial intelligence applied to health, which has developed a subgroup discovery algorithm particularly suited to this type of research topic¹, both partners hope to open up new avenues towards a better understanding of the factors of response to immunotherapy, and contribute to better targeting of these treatments. Gustave Roussy and Quinten Health have already successfully collaborated in the past on similar topics².

¹ https://www.frontiersin.org/articles/10.3389/frai.2020.559927/full
² https://pubmed.ncbi.nlm.nih.gov/27802208/
.

SHARE THIS

latest articles

Thumbnail presenting format and title of the article "A natural language processinf approach to automate Patients' testimonials analysis"
2022, 24 November

Discover our new work around patients’ perce...

The poster "𝘼 𝙉𝙖𝙩𝙪𝙧𝙖𝙡 𝙇𝙖𝙣𝙜𝙪𝙖𝙜𝙚 𝙋𝙧𝙤𝙘𝙚𝙨𝙨𝙞𝙣𝙜 (#𝙉𝙇𝙋) 𝘼𝙥𝙥𝙧𝙤𝙖𝙘𝙝 𝙩𝙤 𝘼𝙪𝙩𝙤𝙢𝙖𝙩𝙚 𝙋𝙖𝙩𝙞𝙚𝙣𝙩𝙨’ 𝙏𝙚𝙨𝙩𝙞𝙢𝙤𝙣𝙞𝙖𝙡𝙨 𝘼𝙣𝙖𝙡𝙮𝙨𝙞𝙨" was written in collaboration with Mélissa...